Trial Profile
An Open-label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect and Dose Proportionality of CC-292 Spray Dried Dispersion Formulation in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2022
Price :
$35
*
At a glance
- Drugs Spebrutinib (Primary) ; Omeprazole
- Indications Chronic lymphocytic leukaemia; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 03 Jun 2022 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 07 May 2015 New trial record